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Abstract. Mass administration of ivermectin (IVM) has signiﬁcantly reduced onchocerciasis prevalence, intensity, and
morbidity in most endemic areas. Most IVM clinical trials were performed long ago in persons with high-intensity infections that are uncommon in West Africa today. This cohort treatment study recruited participants from a hypoendemic
area in eastern Ghana to reevaluate the efﬁcacy and tolerability of IVM with a special focus on the kinetics of microﬁlaria
(Mf) clearance. Mf in the skin and anterior chambers (AC) were assessed by skin snip and slit lamp examinations at baseline and at 3 and 6 months after treatment with IVM 150 mg/kg. Most participants (184–231, 79.7%) enrolled were
treatment-naïve. The baseline geometric mean skin Mf count was 12.67/mg (range 3–86). Although persons with MfAC
at baseline (64/231, 27%) had signiﬁcantly higher skin Mf counts than people without MfAC, 7 of 39 (15%) of persons
with skin Mf counts in the range of 3–5 Mf/mg had MfAC. Skin Mf were detected in 14% (31/218) and 45% (96/216) of
participants 3 and 6 months after IVM treatment, respectively. MfAC were detected in 12 of 212 (5.7%) study participants
at 6 months. 81% (187 of 231) of participants experienced 439 adverse events within 7 days after treatment; all adverse
events were mild (96.1%) or moderate. This study has provided new data on the kinetics of Mf in the skin and eyes after
IVM treatment of persons with light to moderate intensity Onchocerca volvulus infections that are common in Africa at
this time.

INTRODUCTION

IVM may have suboptimal activity against O. volvulus in
savannah regions in Ghana.13 Therefore, one goal of this
study was to reevaluate the efﬁcacy and tolerability of IVM
for treatment of onchocerciasis in Ghana with a special
focus on the kinetics of Mf clearance from the skin and eyes.
Ophthalmological monitoring included optical coherence
tomography (OCT),14 which had not previously been used in
patients with onchocerciasis. Another goal of this study was
to identify participants for a planned future study of a new
treatment of onchocerciasis that requires pretreatment with
IVM to reduce Mf counts.

Onchocerciasis is a parasitic infection that is caused by
the ﬁlarial nematode Onchocerca volvulus and transmitted
by the bite of Simulium blackﬂies that breed in rivers. Larval
parasites (microﬁlariae or Mf) migrate through the skin and
can cause severe cutaneous and ocular disease (“river blindness”). The World Health Organization (WHO) estimates that
at least 25 million people are infected, most of whom reside
in 31 sub-Saharan African countries.1,2 Onchocerciasis is
the world’s second leading infectious cause of blindness.
An estimated one million people have severe visual impairment or blindness because of onchocerciasis. Mass drug
administration (MDA) with ivermectin (IVM) for onchocerciasis has signiﬁcantly reduced the burden of infection to the
point where severe ocular disease is now uncommon in
most endemic areas.2 However, because IVM has no permanent effect on adult worms that can live for more than 10
years, the use of IVM alone for onchocerciasis elimination
has been most successful in areas with low transmission or
in focal transmission zones in the Americas3 Senegal and
Mali4 or Northern Sudan.5 Other groups have reported that
10 or more rounds of IVM were not sufﬁcient to interrupt
transmission in some areas.6–8 Thus, there is an urgent need
to ﬁnd new drugs or novel combinations of existing drugs
that can kill or sterilize adult worms if onchocerciasis is to be
eliminated within a reasonable time frame.9,10
Most studies of IVM in onchocerciasis were performed
long ago in persons with high intensity infections that are
rarely seen today.11,12 Recent studies have suggested that

METHODS
Ethical approval, registration, and study protocol. This
study is registered at CLINICALTRIALS.gov (NCT03517462).
The full study protocol is provided as S1 Appendix to this
paper. Brieﬂy the primary objective of the study was to
determine the proportion of participants who had complete
Mf clearance from the eye at 3 and 6 months following IVM
treatment. Secondary objectives were to assess the kinetics
of the clearance of Mf from the eyes and skin after IVM treatment and to assess the utility of ocular coherence tomography (OCT) for evaluating ocular tissues and intraocular
parasites in persons with onchocerciasis. The protocol was
reviewed and approved by ethical review committees at the
University of Health and Allied Sciences (UHAS) in Ho,
Ghana, the Ghana Health Service, Case-Western Reserve
University (Cleveland, OH) and Washington University School
of Medicine (St. Louis, MO).
Inclusion and exclusion criteria. Inclusion criteria
included persons between the ages of 16 and 70 with at
least one palpable subcutaneous nodule (onchocercoma)
and $ 1 Mf/mg of skin. Persons who met those criteria were
excluded if they were pregnant or breastfeeding mothers
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within one month of delivery, had a history of allergy or intolerance to IVM, or had been treated with IVM within the past
six months. The protocol also excluded persons with serious
baseline ocular disease such as glaucoma, severe keratitis,
uveitis, or cataracts that interfered with visualization of the
posterior segment of the eye.
Screening and participant enrollment. Screening and
recruitment were performed in Nkwanta North District in
the Volta region of Ghana. Participants were from villages
that are hypoendemic for onchocerciasis (nodule prevalence , 20%), and mass administration of IVM had not yet
been implemented in these villages. The study team met
with community leaders and local health personnel in the
study area and held open community meetings to explain
the purposes and plans for the study prior to screening
and recruitment of participants. The meetings and consent
forms were in English and a local language (either Twi or
Ewe) understood in the study area. Participation required
written consent for adults and written consent from a parent or guardian plus assent for minors less than 18 years
of age.
Persons were initially screened for the presence of onchocercal nodules by manual palpation. Persons with nodules
were tested for microﬁladermia as follows. Four skin snips
were collected (one from each posterior iliac crest and each
posterior calf) with a Holth corneoscleral punch. Snips were
weighed and incubated in 100 mL of isotonic saline in individual wells of a ﬂat-bottomed microtitre plate at ambient temperature for at least 8 hours. Snips were then examined by
indirect microscopy, and Mf were counted by experienced
microscopists. Mean values for Mf/mg for four snips were
calculated.
Medical history and physical examinations. A brief
medical history reviewed prior illnesses and current medications. A review of systems was performed to identify baseline symptoms with special attention to any history of prior
onchocercal eye or skin disease or treatment. The physical
examination included height, weight, and vital signs with
special attention to skin lesions and lymph nodes.
Ophthalmological examinations. Study participants
were evaluated with a panel of tests two days prior to IVM
treatment. Details are provided in the protocol (Supplemental File 1). Brieﬂy, the panel included tests of visual acuity,
visual ﬁelds, pupillary reﬂex, applanation tonometry, indirect
ophthalmoscopy, fundus photography and optical coherence tomography (OCT), which provides detailed images of
the posterior segment including the retina. Slit lamp examinations were performed to assess ocular abnormalities in
the cornea and anterior segment. Participants sat with their
heads bent as far forward and down for at least three
minutes prior to the slit lamp examination to optimize visualization of Mf in the anterior chamber (AC).
Drug treatment, adverse event (AE) assessments, and
follow-up. Eligible, consenting study participants were
treated with 150 mg/kg of IVM per os under direct observation.
Participants were housed in the UHAS School of Public Health
Research Center, which is located within the grounds of the
Hohoe Government Hospital in Hohoe, Ghana. Participants
were evaluated daily for 7 days after treatment and asked
whether they had symptoms suggestive of systemic (e.g.,
fever, headache), cutaneous, or ocular AEs. A study physician
performed a directed physical examination for all participants.
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All participants had a full ophthalmological examination as
described above on day 7 after IVM treatment. Skin snip tests
and the full battery of ophthalmological tests were repeated at
3 and 6 months after IVM treatment.
Data management. Participant data were recorded on
paper case report forms and later entered into REDCap at
the UHAS School of Public Health; that data center also
validated and cleaned the data. REDCap ﬁles included participant’s study identiﬁcation numbers without personal
identiﬁers. A parallel participant key linked study ID numbers
with personal identifying information (name, date of birth).
Encrypted REDCap data were transferred to a dedicated
server housed at Washington University in St. Louis. A data
manager at Washington University performed additional
data cleaning and validation and communicated with the
UHAS data manager and study investigators to clear queries
prior to data lock.
Statistical methods. Descriptive statistics were calculated as frequencies and proportions for categorical variables, medians and interquartile ranges (IQRs) for continuous
variables, and geometric means and ranges for highly
skewed continuous variables. All correlations between variables of interest were calculated using Spearman rank correlations. Additional statistical comparisons were performed
using x2 and Fisher’s exact tests for categorical variables,
t-tests for continuous variables, and Mann–Whitney U tests
for skewed continuous variables. The total ocular Mf count
(MfAC) was calculated by summing the numbers of Mf identiﬁed in the AC of each eye. All data analysis was conducted
in SAS for Windows version 9.4 (SAS Institute, Cary, NC),
and a 5 0.05 was used to determine statistical signiﬁcance.
RESULTS
Enrollment and treatment. A total of 1,030 subjects who
were screened near Kpassa (the capital of Nkwanta North
district) had at least one palpable subcutaneous nodule. Of
these, 274 with at least 1 Mf/mg of skin were invited to
Hohoe (170 km south of Kpassa) for secondary screening.
Thirteen people were not able to make the trip. Thirty people
were excluded because of severe ocular disease, other signiﬁcant comorbidities or pregnancy. Characteristics of the
study sample with skin Mf data over time are presented in
Table 1. Thus, 231 people were enrolled into the study with
full baseline examinations and treatment with IVM. Most participants (184/231, 79.7%) were treatment-naïve prior to this
study (no prior IVM). Only 27 of 231 (11.7%) of study participants had received IVM in the 3 years prior to our study.
Mf counts in the skin and eyes before and after
treatment. Baseline and follow-up skin Mf data are summarized in Table 1. The median number of palpated nodules
per participant at baseline was 2 (IQR: 1, 3), and skin Mf
counts were signiﬁcantly correlated with nodule number
(Spearman rank correlation 0.191, P 5 0.004). Skin Mf
counts in persons who had received IVM in the past 3 years
tended to be lower than those in people who had no treatment in the past 3 years. Geometric means and ranges were
9.0 (3–49) versus 13.2 (3–86), respectively (P 5 0.036). Ocular Mf were less commonly seen in persons who had
received IVM in the past 3 years, but the difference was
not statistically signiﬁcant (60/204 [29.4%] versus 2/27,
[14.8%], P 5 0.11).

742

OPOKU AND OTHERS

TABLE 1
Descriptive characteristics of study participants and skin snip Mf data over time*
Variable

Gender
Age at baseline (years)
BMI at baseline (kg/m2)
Mean skin Snip Mf count (Mf/mg)
Mf prevalence (any snip)

Group

Female
Male
Baseline
3 months
6 months
Baseline
3 months
6 months

Descriptive statistics

92
139
39.1
19.6
12.66
0.07
0.31
231/231
31/218
96/212

(39.8%)
(60.2%)
(29.2, 52.4) [231]
(18.5, 21.3) [229]
(3, 86.29) [231]
(0, 11.28) [218]
(0, 5.74) [212]
(100%)
(14.2%)
(45.3%)

*Gender and skin snip positivity for microﬁlariae (Mf) are reported as n (%). Numbers of participants are shown in brackets. Age and BMI are reported as median (IQR), and skin snip Mf counts are
reported as geometric mean (range).

Most participants were restudied at 3 and 6 months
(95.7% and 91.8%, respectively). Skin Mf prevalence and
densities were dramatically reduced after IVM treatment.
Most study participants had negative skin snips 7 days after
treatment (data not shown). Although the geometric mean
Mf density in skin snips was reduced by 95.7% from baseline 6 months after IVM treatment, 45.3% of 212 participants
tested had Mf in skin snips at that time. Baseline skin snip
Mf counts were higher in participants with positive skin snips
at 6 months than in those with negative skin snips at that
time (geometric means, 17.1 versus 8.85, P , 0.001).
Changes in skin snip Mf counts in individual participants
after IVM treatment are shown in Figure 1A. Note the Log
scale for Mf counts. The ﬁgure shows that many people with
negative skin snips at 3 months had Mf detected at 6
months. It also shows that skin Mf counts decreased only
slightly after IVM treatment in three participants (1.4% of 212
persons tested 6 months after treatment).

baseline, 7 days, 3 months, and 6 months after treatment,
respectively. Three participants with negative MfAC at baseline had MfAC 6 months after treatment. Two of these persons had MfAC on day 7, but one had no MfAC detected at
baseline or day 7.
MfAC at baseline were no more common in males than in
females (P 5 0.88). Baseline skin Mf counts (Mf/mg) for persons without and with MfAC at baseline were 10.6 (range
3–68) and 20.0 (3–86.3), respectively (P , 0.001). More
details on the frequency of MfAC by skin snip Mf count are

OCULAR FINDINGS BEFORE AND AFTER TREATMENT
No Mf were detected in the posterior segment in any participants’ eyes by any method, and no corneal Mf were seen.
Baseline ocular disease in enrolled participants identiﬁed
without OCT included macular scarring (N 5 10, 4.3%), cataract (N 5 3, 1.3%), optic atrophy N 5 1, 0.43%), and other
(2.1%). Sixteen persons (6.9% of 231 participants) had ﬁndings that were considered suspicious but non-diagnostic for
glaucoma; no participant had elevated intraocular pressure.
Baseline OCT ﬁndings in the enrolled subjects included chorioretinal atrophy and scarring (N 5 15), macular drusen
(N 5 8, 3.5%), epiretinal membrane (N 5 1), cystoid macular
edema (N 5 1). More details on opthalmological abnormalities will be reported separately.
Ocular Mf data before and after treatment are shown in
Table 2 and Figure 1B. Sixty-four (27.7%) of study participants had Mf visible in the anterior chamber (MfAC) detected
by slit-lamp examination in one or both eyes at baseline. The
median time that participants held their heads down prior to
examination was 12 minutes (IQR: 10–17). There was a weak
correlation between time with head down and baseline
MfAC counts (Spearman rank correlation 0.09, P 5 0.176).
The MfAC data include results from one outlier who had very
high MfAC counts before and after treatment. No other participant had a MfAC count . 3 (total for both eyes) at 6
months. Percentages of participants with more than 5 Mf
visible in either AC were 7.8%, 10.8%, 1.8%, and 0.5% at

FIGURE 1. Microﬁlaria (Mf) counts in skin (A) and eyes (B) in individuals at baseline and after ivermectin treatment.

743

IVERMECTIN TREATMENT OF ONCHOCERCIASIS IN EASTERN GHANA

TABLE 2
Prevalence and densities for ocular microﬁlariae in the anterior chamber (MfAC) before and after ivermectin treatment
Left eye
Time point

Baseline
7 days
3 months
6 months

n/N (%)

45/231
55/231
5/218
8/212

Right eye

Geometric mean (range)

(19.5%)
(23.8%)
(2.3%)
(3.8%)

2.67
2.5
8.37
1.73

(1,
(1,
(3,
(1,

50)
30)
20)
15)

n/N (%)

47/231
54/231
12/218
7/212

(20.3%)
(23.4%)
(5.5%)
(3.3%)

One or both eyes (sum)

Geometric mean (range)

2.9
3.58
2.73
2.09

(1,
(1,
(1,
(1,

100)
80)
40)
20)

n/N (%)

64/231
73/231
14/218
12/212

(27.7%)
(31.6%)
(6.4%)
(5.7%)

Geometric mean (range)

3.4
3.89
3.73
1.98

(1,
(1,
(1,
(1,

150)
82)
60)
35)

Geometric mean and range calculations only considered data from individuals with MfAC detected.

provided in Table 3. MfAC were observed seven days after
treatment in 32 of 167 (19.2%) persons with no ocular Mf
detected at baseline. Thus, 96 of 231 (41.6%) of study participants had MfAC detected by slit lamp examinations at
baseline and/or on day 7. It was also interesting that 23 of 64
(35.9%) persons with MfAC detected at baseline had no
MfAC detected on day 7.
MfAC prevalences and densities decreased signiﬁcantly at
the 3- and 6-month time points in most study participants
after IVM treatment (Table 2 and Figure 1B) (P , 0.01 for
both comparisons). However, MfAC were detected in 12 of
212 (5.7%) study participants who were examined at 6
months; 3 persons with low MfAC counts at 6 months did
not have MfAC recorded at baseline. Two of these persons
had MfAC detected 7 days after treatment. The person with
150 MfAC at baseline had 35 MfAC at 6 months; the other
11 persons with MfAC at 6 months had MfAC values
between 1 and 3 at that time. A univariable analysis showed
that baseline skin Mf counts, presence of MfAC, and MfAC
counts (sum for both eyes) at baseline were all signiﬁcant
risk factors for MfAC 6 months after IVM treatment (P 5 0.01,
0.005, and , 0.001, respectively). However, the presence of
MfAC at 6 months was not signiﬁcantly more common in
persons with positive skin snips at that time.
Adverse events recorded during the first 7 days after
IVM treatment. Early onset AEs are listed in Supplemental
Table 1. One or more adverse events were recorded for 187
of 231 participants (81%) within 7 days of treatment. A total
of 439 separate AEs were recorded during this 7-day period.
Of these, 422 were mild (Grade 1) and 17 were moderate
(Grade 2). No severe or serious AEs were recorded. Most
AEs were mild or moderate Mazzotti reactions. The most
common general (non-ocular) AEs were itching skin (40.3%),
headache (23.4%), and joint or muscle pain (19.5%). The
most common ocular AEs were itching (6.9%) and pain
(4.3%); all ocular AEs were Grade 1. Most ocular and general
AEs occurred by day 1 after treatment, and they were of
short duration; few AEs were recorded after day 3, and none
on day 7. A univariable analysis showed that none of the
TABLE 3
Baseline frequency of MfAC by mean skin snip Mf/mg
Frequency (%) of MfAC in either eye
Mean skin snip Mf/mg

3–5
. 5 to 10
. 10 to 20
. 20 to 30
. 30
Total

No

Yes

Total

39
50
41
13
24
167

7 (15.2)
11 (18.0)
12 (22.6)
8 (38.1)
26 (52)
64 (27.7)

46
61
53
21
50
231

MfAC. Microﬁlaria(e) (Mf) present in either anterior chamber detected by slit lamp
examination.

baseline characteristics considered (sex, age, BMI, skin Mf
count, and MfAC) were signiﬁcant risk factors for AEs within
7 days after IVM treatment.
Adverse events at later time points. AEs recorded during participant evaluations performed at 3 and 6 months
after treatment are listed in Supplemental Table 2. Almost
58.5% of participants had one or more AEs recorded at
these time points. The most common AE was ocular itching
(13.4% of participants). Most other AEs recorded at these
later time points seemed to be unrelated to O. volvulus infection or IVM treatment. Three study participants experienced
severe or serious AEs after the 7-day inpatient observation
period. One participant experienced a severe (Grade 3) reaction to a bee sting. One participant required a limb amputation for gangrene (a SAE), and one participant had a fatal
serious adverse event (liver failure because of metastatic gall
bladder cancer that was diagnosed months after treatment).
These severe and serious AEs were judged by study physicians and the Medical Monitor to have been unrelated to
IVM treatment.
DISCUSSION
This study has provided detailed data on IVM’s current
efﬁcacy and on the kinetics of Mf reductions in the eyes and
skin in persons with light to moderate O. volvulus infections
in a hypoendemic area in a forest-savannah transition zone
in eastern Ghana. Although some might consider light infections to be a limitation of this study, our results may be more
relevant to the current status of onchocerciasis in Africa than
those from clinical trials that were performed in more heavily
infected persons in the 1980s.11,15,16 That is because IVM
(provided alone as CDTi or provided as MDA with albendazole in areas with coendemic lymphatic ﬁlariasis) has been
very widely used in sub-Saharan Africa in recent years. For
example, 152.9 million treatments were distributed in WHO’s
Africa region in 2019 (70.4% of the total targeted population).2 Preventive chemotherapy with IVM over many years
has reduced the prevalence and intensity of onchocerciasis
infections in most endemic areas and interrupted transmission in some foci.17,18 It is interesting to compare results
from this study to those from persons who were treated with
IVM in a phase 3 clinical trial that compared the efﬁcacy of
IVM and moxidectin (the “moxidectin trial”).19 That study
was conducted approximately 10 years before our study in
persons with heavier parasite burdens. The geometric mean
skin Mf/mg values in the moxidectin trial and in the present
study were 32.2 and 12.7, respectively, and many more participants in the moxidectin trial had $ 10 MfAC at baseline
than in the present study (15% versus 6.9%, respectively).
These differences in baseline infection intensities resulted in
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different treatment outcomes. For example, only 11% of IVM
recipients in the moxidectin trial had negative skin snips
6 months after treatment versus 54% in the present study.
Indeed, 46% of the participants in our study had baseline
skin Mf counts below the 10/mg required for inclusion in the
moxidectin trial. We believe that this fact increases the relevance of our study for onchocerciasis during an era when
WHO is aiming for elimination rather than control. We believe
that relatively few areas in Africa outside of the loiasis belt
currently have onchocerciasis prevalences and intensities
comparable to those in the moxidectin trial study sites.
IVM was effective for clearing Mf from the skin in this
study, and few participants had positive skin snips 7 days
after treatment. In contrast, changes in MfAC were variable
but not dramatic 7 days after treatment. Mf reappeared in
skin snips in many participants between 3 and 6 months
after treatment, as expected. Although a small number of
participants had only slight reductions in skin Mf counts
between baseline and 3 months, skin Mf counts did not
increase between 3 and 6 months in those participants.
Thus, suboptimal responses to IVM treatment as reported
from other areas in Ghana13 were not common in this study.
This study yielded some unexpected results. For example,
we expected MfAC to be quite uncommon in persons with
skin mf counts below 20/mg. Although baseline MfAC frequencies were correlated with skin Mf counts, 27.7% of all
persons in our study of persons with mostly light to moderately infections had MfAC at baseline, and MfAC was present in 15.2% of persons with baseline skin Mf counts
between 3 and 5 Mf/mg. We also expected MfAC to be rare
6 months after IVM treatment in persons with light to moderate infections based on prior publications.16,20 Thus, we
were somewhat surprised that 5.7% of participants had
MfAC present 6 months after IVM treatment. Although only
one participant in our study had a MfAC count . 3 in either
eye 6 months after treatment, this result and the presence of
MfAC 12 months after IVM in a signiﬁcant number of participants in the moxidectin trial show that a single pretreatment
dose of IVM does not guarantee clearance of MfAC. Indeed,
several participants who were treated with IVM in the moxidectin trial had high MfAC counts after IVM that were comparable to that seen in the outlier in our study. Finally, we
were also surprised by how often MfAC was detected 7 days
after treatment in persons with negative baseline slit lamp
exams. This suggests that a single slit lamp examination is
insensitive for detecting MfAC when counts are low, as in
this study. We doubt that this was caused by movement of
Mf into the eyes shortly after treatment. Of course, MfAC
results can vary from day to day in persons with low MfAC
counts, and Mf may have been easier to see in the AC after
they were paralyzed by IVM. To improve MfAC detection,
our future studies will require participants to bend their head
forward and further downward for at least 10 minutes just
prior to slit lamp examinations.
The ﬁnding that mild or moderate AEs were common in
the days following IVM treatment was consistent with prior
reports.11,15 Detailed ophthalmological results will be
reported separately. Although OCT examinations provided
some interesting results, they did not detect intraocular AEs
after IVM treatment.
In conclusion, this study has provided interesting data on
the continued efﬁcacy and tolerability of IVM in a population

with light to moderate O. volvulus infections that are common in Africa at this time. Ophthalmological testing in this
study included the ﬁrst use of OCT in an onchocerciasis clinical trial. This IVM study provides a good foundation for studies of new treatments for onchocerciasis, and it has provided
a cohort of candidates for a planned trial of a new treatment
that requires pretreatment with IVM.
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